Title: Characteristics and Outcomes of COVID-19 Patients in New York City's Public Hospital System

Authors

Roopa Kalyanaraman Marcello, MPH1 Johanna Dolle, MPA1 Sheila Grami, MPH1 Richard Adule Zeyu Li, MPH1 Kathleen Tatem, MPH1 Chinyere Anyaogu, MD, MPH2 Stephen Apfelroth, MD3 Raji Ayinla, MD4 Noella Boma, MD5 Terence Brady, MD6 Braulio F. Cosme-Thormann, MD7 Roseann Costarellas Kenra Ford, MBA8 Kecia Gaither, MD, MPH9 Jessica Jacobson, MD10 Marc Kanter, MD9 Stuart Kessler, MD11 Ross B. Kristal, MD12

Joseph J. Lieber, MD11 Vikramjit Mukherjee, MD10 Vincent Rizzo, MD, MBA13 Madden Rowell, MD12 David Stevens, MD14 Elana Sydney, MD3 Andrew Wallach, MD12 Dave A. Chokshi, MD, MSc1 Nichola Davis, MD, MS1 New York City Health + Hospitals COVID-19 Population Health Data Team1

Affiliations

- 1. New York City Health + Hospitals, Office of Population Health
- 2. New York City Health + Hospitals/North Central Bronx
- 3. New York City Health + Hospitals/Jacobi
- 4. New York City Health + Hospitals/Harlem
- 5. New York City Health + Hospitals/Metropolitan
- 6. New York City Health + Hospitals/Coney Island
- 7. New York City Health + Hospitals/Woodhull
- 8. New York City Health + Hospitals, Office of Medical & Professional Affairs
- 9. New York City Health + Hospitals/Lincoln
- 10. New York City Health + Hospitals/Bellevue
- 11. New York City Health + Hospitals/Elmhurst

12. New York City Health + Hospitals, Office of Ambulatory Care

- 13. New York City Health + Hospitals/Queens
- 14. New York City Health + Hospitals/Kings County

Corresponding Author

Roopa Kalyanaraman Marcello, MPH

New York City Health + Hospitals

50 Water Street, 9th Floor

New York, NY 10004

marcellr@nychhc.org

917.601.8311

Word Count: 3004

Abstract

Background

New York City (NYC) has borne the greatest burden of COVID-19 in the United States, but information about characteristics and outcomes of racially/ethnically diverse individuals tested and hospitalized for COVID-19 remains limited. In this case series, we describe characteristics and outcomes of patients tested for and hospitalized with COVID-19 in New York City's public hospital system.

Methods

We reviewed the electronic health records of all patients who received a SARS-CoV-2 test between March 5 and April 9, 2020, with follow up through April 16, 2020. The primary outcomes were a positive test, hospitalization, and death. Demographics and comorbidities were also assessed.

Results

22254 patients were tested for SARS-CoV-2. 13442 (61%) were positive; among those, the median age was 52.7 years (interquartile range [IQR] 39.5-64.5), 7481 (56%) were male, 3518 (26%) were Black, and 4593 (34%) were Hispanic. Nearly half (4669, 46%) had at least one chronic disease (27% diabetes, 30% hypertension, and 21% cardiovascular disease). Of those testing positive, 6248 (46%) were hospitalized. The median age was 61.6 years (IQR 49.7-72.9); 3851 (62%) were male, 1950 (31%) were Black, and 2102 (34%) were Hispanic. More than half (3269, 53%) had at least one chronic disease (33% diabetes, 37% hypertension, 24% cardiovascular disease, 11% chronic kidney disease). 1724 (28%) hospitalized patients died. The median age was 71.0 years (IQR 60.0, 80.9); 1087 (63%) were male, 506 (29%) were Black, and 528 (31%) were Hispanic. Chronic diseases were common (35% diabetes, 37% hypertension,

28% cardiovascular disease, 15% chronic kidney disease). Male sex, older age, diabetes, cardiac history, and chronic kidney disease were significantly associated with testing positive, hospitalization, and death. Racial/ethnic disparities were observed across all outcomes.

Conclusions and Relevance

This is the largest and most racially/ethnically diverse case series of patients tested and hospitalized for COVID-19 in the United States to date. Our findings highlight disparities in outcomes that can inform prevention and testing recommendations.

Introduction

SARS-CoV-2 (COVID-19) emerged in December 2019 in Wuhan, China, and it rapidly spread across the world. The United States currently has the most COVID-19 cases globally, and New York City (NYC) is the most affected region, with more than 184000 confirmed cases and more than 15100 confirmed deaths as of May 12, 2020.1 The city's public hospital system has cared for a disproportionate number of cases, with many of its hospitals having neared capacity and having needed additional support.

Reports published to date on COVID-19 patients in NYC have been of cohorts within private health systems that typically serve primarily insured, higher-income patients.2,3,4,5,6,7 Additionally, these reports primarily present data only on individuals who have tested positive or have been hospitalized; analyses of characteristics of all patients presenting for testing and their sequelae are lacking. Furthermore, data are limited on patients reflecting the full racial and ethnic diversity of NYC and a wider spectrum of socioeconomic statuses. Identifying characteristics that are associated with a positive test result, hospitalization, and death can help refine public health policy and improve care for groups who are at highest risk of illness and hospitalization.

We describe here the results of our analysis of the demographic and clinical characteristics and outcomes of patients tested for COVID-19 and admitted to New York City's public hospital system, the largest case series in NYC and the United States reported to date. Methods

Study Setting

New York City Health + Hospitals (NYC H+H) is the largest public health care system in the country. It provides inpatient, outpatient, and home- and community-based services to more than 1 million New Yorkers each year at more than 70 facilities across the city's five boroughs.

The majority of NYC H+H's patients are low-income: one third (32%) are uninsured and another one third (35%) are Medicaid beneficiaries. Additionally, more than 70% of patients are people of color, many of whom are immigrants. The system includes 11 acute care hospitals, which were the primary setting for this study.

Data Sources

We extracted medical records for all patients tested for SARS-CoV-2 at any NYC H+H location between March 5 and April 9, 2020. Patients were followed up for primary outcomes (test result, hospitalization, and in-hospital death) through April 16, 2020.

Test results were based on real-time reverse transcriptase polymerase chain reaction (RT-PCR) assays of nasopharyngeal swabs. Initially, assays were conducted by the New York City Department of Health and Mental Hygiene and LabCorp. Starting on March 19, 2020, all tests were processed by BioReference Laboratories. Starting on April 1, 2020, NYC H+H performed some tests using the Cepheid GeneXpert Express SARS-CoV-2 assay. COVID-19 patients were defined as those with a laboratory-confirmed positive test. Hospitalized patients were defined as those who were admitted on or after the date of their test. Patients who died were defined as those with a death recorded in the inpatient setting.

Data on age, sex, race/ethnicity, BMI (calculated from most recent height and weight), and comorbidities were extracted from patients' electronic health record (EHR) where available. Comorbidities were defined as the presence or absence of the following chronic conditions recorded as billing diagnoses or "active" in a patient's problem list in the EHR: diabetes, hypertension (HTN), arrhythmia, cardiovascular disease (CVD), congestive heart failure (CHF), asthma, chronic obstructive pulmonary disease (COPD), chronic kidney disease (CKD), liver disease, cancer, HIV, and a flag for having one or more specified chronic disease (diabetes, HTN, CVD, asthma, COPD, or CKD). We selected these based on prior published reports and current clinical experience with COVID-19 patients at NYC H+H.2,8,9,10

Statistical Analysis

We used descriptive statistics to characterize all patients who were tested and hospitalized during the study and follow up periods and who had recorded values for specified variables. Age was expressed as a median and interquartile range, with ranges provided that align with current citywide reporting. Categorical variables were summarized with counts and percentages.

All analyses were performed with the use of R software version 3.6.2 (R Foundation for Statistical Computing). Tests of significance were conducted using Pearson chi-square tests. We considered a p-value of <0.05 to be statistically significant.

This study was approved by the Biomedical Research Alliance of New York Institutional Review Board. Waivers of informed consent and of the Health Information Portability and Privacy Act were granted due to the retrospective nature of the study.

Results

During the study period, 22254 patients were tested for COVID-19. 78 (0.3%) of these patients did not have a test result available at the end of the follow up period and were excluded from this analysis. Of the 22176 patients with a test result, 13442 (61%) tested positive; 6248 (46%) of patients who tested positive were hospitalized and 1724 (28%) of hospitalized patients died (**Figure 1**).

Of the 13442 individuals with laboratory-confirmed SARS-CoV-2 infection, 7481 (56%) were male; males were significantly more likely to test positive than females (56% vs. 44% of all positive tests, respectively, p<0.001). The median age of individuals who tested positive was 52.7 (39.5, 64.5). 5506 (41%) patients were 45-64 years old and 104 (1%) were under 18 years

of age. Older age was significantly associated with a positive test result (21% among ages 0-17 and 78% among age 75 and older, p<0.001).

Race/ethnicity was available for 22107 (99.7%) of the 22176 patients with a test result. Of those who tested positive, 3518 (26%) were Black and 4593 (34%) were Hispanic. An additional 3276 (24%) were of other or unknown race/ethnicity. Black race and Hispanic ethnicity were significantly associated with testing positive. See **Table 1** for full results and **Figure 2** for test results by demographic groups.

BMI was available for 15828 (71%) of tested individuals; we found that BMI \geq 25 was significantly associated with testing positive. A diagnosis history was available for 16420 (74%) individuals who were tested. The most common chronic diseases were diabetes (27%), HTN (30%), and CVD (21%). The presence of at least one chronic disease was significantly associated with testing positive (46% vs. 38%), particularly for those with diabetes (27% vs 17%), HTN (30% vs. 22%), and CKD (8% vs. 5%) (for all, p<0.001). Individuals with asthma and COPD were significantly less likely to test positive (7% vs. 11% and 3% vs. 5%, respectively, p<0.001 for both) (**Table 1**).

Table 2 displays the demographics and clinical characteristics and hospitalization outcome of patients with a positive test result. Nearly half of patients who tested positive (6248, 46%) were hospitalized. Males comprised nearly two-thirds (3851, 62%) of hospitalized patients, and male sex was significantly associated with hospitalization (p<0.001). As compared to females, a greater proportion of males were hospitalized (51% vs. 40%).

The median age of hospitalized patients was 61.6 years (IQR 49.7, 72.9); the overwhelming majority of patients were over the age of 45, with 2491 (40%) between ages 45 and 64, 1303 (21%) between ages 65 and 74, and an additional 1322 (21%) age 75 and older.

Among individuals who tested positive, older age was significantly associated with hospitalization, with 24% of individuals age 18-44 and 89% of individuals age 75 and older hospitalized.

Blacks and Hispanics each comprised approximately one-third of hospitalized patients (31% and 34%, respectively); black race was significantly associated with hospitalization. Additionally, Blacks were more likely to be hospitalized than individuals of other racial/ethnic groups (55% vs. 46% for both Hispanics and Whites and 43% for APIs). Full results of hospitalization rates by demographic factors are in **Figure 3**.

Among individuals who tested positive with a recorded BMI (8759; 65%), hospitalization was significantly more likely among individuals with BMI \geq 40 (9% vs. 5%). A diagnosis history was available for 10169 (76%) of patients who tested positive. Chronic diseases were common among patients who were hospitalized, with 53% having one or more chronic disease, including diabetes (33%), HTN (37%), CVD (24%), and chronic kidney disease (11%). Having at least one chronic disease was significantly associated with hospitalization (53% vs. 35%) as were diabetes (33% vs. 17%), HTN (37% vs. 19%), arrhythmia (8% vs. 3%), CVD (24% vs. 15%), CHF (7% vs. 1%), COPD (4% vs. 1%), liver disease (3% vs. 2%), and CKD (11% vs. 3%) (for all, p<0.001). We found no significant association between asthma, cancer, or HIV and hospitalization (**Table 2**).

Table 3 displays the demographics and clinical characteristics and clinical outcome of hospitalized patients. Of the 6248 hospitalized patients, 1238 (20%) were still admitted at the end of the study period, 3286 (53%) were discharged, and 1724 (28%) died.

Males comprised nearly two-thirds (1087, 63%) of patients who died, and male sex was significantly associated with death. The median age of patients who died was 71.0 years (IQR

60.0, 80.9); the majority of patients were over the age of 65, with 433 (25%) between ages 65 and 74 and 679 (39%) age 75 and older. Increasing age was significantly associated with death.

Blacks and Hispanics each comprised approximately one-third of all patients who died (29% and 31%, respectively), and Whites comprised 12%. White race was significantly associated with death, with a greater proportion of Whites dying than among all other racial/ethnic groups (47% vs. 32% for Blacks, 31% for Hispanics, and 37% for APIs). Full results of death rates by demographic factors are in **Figure 4**.

Among the 5659 (90%) hospitalized patients with a BMI value, individuals with BMI \geq 40 were more likely to die than be discharged (11% vs. 8%), but this association was not significant (p=0.084). Chronic diseases were common among patients who died, with 53% having one or more chronic disease, including diabetes (35%), HTN (37%), CVD (28%), CHF (9%), and CKD (15%). Diabetes, arrhythmia, CVD, CHF, and CKD were significantly associated with death (p<0.001), whereas asthma was significantly associated with discharged (p=0.033) (**Table 3**).

We observed consistent differences across racial/ethnic groups in the age distribution across all outcomes, with Hispanics younger and Whites older than other racial/ethnic groups (**Table 4**). We also observed differences by race/ethnicity in the prevalence of comorbidities among patients who were hospitalized and died (**Table 5**). Among patients who were hospitalized, Hispanics and Blacks had a higher prevalence of obesity than other groups, with 13% of Blacks having a BMI ≥40 as compared to 6% of Hispanics and 8% of Whites. Hospitalized Blacks were also more likely to have one or more chronic disease than other racial/ethnic groups (64% of Blacks vs. 50% of Hispanics and 52% of Whites) and also had a higher prevalence of diabetes, HTN, CVD, CHF, and CKD. These disparities were largely

11

consistent among patients who died, with 15% of Blacks having a BMI \geq 40 as compared to 7% of Hispanics and 8% of Whites and the highest prevalence of one or more chronic diseases among all racial/ethnic groups (62% vs 54% for both Hispanics and Whites and 51% for APIs), including diabetes, HTN, and CKD. Whites who died had the highest prevalence of arrhythmia (17%), CVD (36%), and CHF (15%), and COPD (7%) of all racial/ethnic groups.

Discussion

In this report, we describe demographic and clinical characteristics and outcomes of patients tested for COVID-19 at the largest public hospital system in the nation. Of the 22254 patients who were tested, 13442 patients tested positive, 6248 required hospitalization, and 1724 died. We found that male sex, older age, and certain chronic diseases were significantly associated with all outcomes, with racial/ethnic disparities across all outcomes.

Although male sex was significantly associated with all outcomes, we observed that the proportion of males and females who died were relatively similar (36% and 33%, respectively), unlike with testing positive and hospitalization.

Whereas BMI ≥25 was found to be associated with testing positive, only BMI ≥40 was associated with hospitalization and death, which is consistent with other reports.3,11,12 In addition to the comorbidities associated with a positive test result, cardiac history and COPD were significantly associated with hospitalization. These findings are similar to previous reports showing high rates of chronic diseases, including diabetes and HTN, among COVID-19 patients.5,8,13 We observed fewer comorbidities associated with death, with only diabetes, CVD, CHF, arrhythmia, and CKD having a significant association; these may be driven in part by the older age of patients who died.

Although the presence of certain chronic diseases was associated with all outcomes, we observed a lower likelihood of infection among individuals with asthma and COPD and a lower likelihood of death among individuals with asthma, which is aligned with recent reports of cases in New York State and globally.14,15

A growing body of evidence shows a disproportionate burden of COVID-19 among Hispanics and Blacks in NYC.4,6,7,16 Across all outcomes, we found that Blacks and Hispanics each comprised approximately one-third of the total population, mirroring citywide rates.17 However, these groups were overrepresented as compared to the overall NYC population.18

Hispanics were more likely to test positive than any other racial/ethnic group but, once they tested positive, they were not more likely to be hospitalized or die than other groups, which is likely due to their younger age. Across all outcomes, Hispanics were younger than other racial/ethnic groups: among Hispanics only, individuals ages 18 to 64 comprised 80% of those testing positive, 66% of those hospitalized, and 44% of those who died.

Similarly, Blacks were more likely to test positive and be hospitalized than individuals of other racial/ethnic groups. This is likely driven by their higher prevalence of comorbidities, contributing to their increased risk of hospitalization.¹⁹ However, once hospitalized, Black race and Hispanic ethnicity were significantly associated with being discharged, while Whites were more likely to die. Our analyses of the age distribution and prevalence of comorbidities within each racial/ethnic group suggest that this is driven by the older age of and higher prevalence of CVD, CHF, and arrhythmia among Whites in our cohort. Additionally, Blacks were younger than Whites across all outcomes, indicating a disproportionate burden of illness and mortality among this group. Analyses that utilize multivariable models; control for age, demographics and

comorbidities; and incorporate factors such as ICU admission and end of life decisions are necessary to better understand these disparities.

The disproportionate burden of COVID-19 among Hispanics and Blacks also may be partially explained by their overrepresentation in essential roles that require in-person work, resulting in frequent and prolonged exposure.²⁰ Recent data show that only 16% of Hispanics and 20% of Blacks are able to work at home as compared to 30% of Whites and 39% of APIs, and only 9% of low-wage (<25th percentile) workers are able to work at home as compared to 62% of workers in the highest income quartile.²¹ Additional analyses that incorporate non-clinical data related to the social determinants of health will be valuable in expanding upon these findings.

Post-hoc, exploratory analyses indicate that Whites and APIs were more likely to have been tested in outpatient, non-emergency settings than Blacks and Hispanics, who were more often tested in the emergency department and inpatient settings. This may partially account for the lower positivity rates among Whites and APIs and higher hospitalization rates among Blacks and Hispanics, who may have been presenting with a longer duration and greater severity of illness. Analyses that assess testing location and symptoms at presentation can help elucidate these disparities and inform recommendations for seeking care.

To date, published reports on COVID-19 in the NYC area have been of smaller cohorts with less racial/ethnic diversity than at NYC H+H. The largest such case series reported to date was of 5700 hospitalized patients, of whom 23% were Black and 23% Hispanic; in contrast, Blacks and Hispanics comprised 31% and 34%, respectively, of the 6248 patients hospitalized for COVID-19 at NYC H+H, more closely reflecting the demographics of the overall NYC population._{6,22} Given the diversity of NYC and the outsize and growing impact of COVID-19 on

14

communities of color, it is important that reports on COVID-19 in the United States proportionally represent these populations.

Limitations

Our study includes several limitations. BMI and clinical history were not uniformly available for the study population, with a greater proportion of non-hospitalized patients missing such a history. Having diagnoses recorded in the EHR was correlated with hospitalization, as, in many cases, a diagnosis history was completed upon admission as a part of the patient's COVID-19 care plan.

Additionally, some individuals had incomplete documentation of comorbidities due to variations in the format of historical electronic databases. NYC H+H recently completed a transition to a single EHR platform for the entire health system, resulting in data from the previous platform not being uniformly carried over to the current platform.

Community testing was initially available at ambulatory sites and temporary appointment-only drive-through sites but was restricted starting on March 20 to individuals presenting at an emergency department with severe symptoms.23,24,25 Because the criteria for testing in NYC became more strict toward the end of the study period, individuals whose tests and hospital admissions were in the later portion of the study period were more likely to test positive or have more severe illness that required hospitalization. While this may reduce the generalizability of findings to other localities with a lower burden of COVID-19 and, accordingly, less restrictive testing policies, our findings are aligned with those from other health systems in the NYC area.

Our set of hospitalized patients includes individuals who were admitted for any reason after receiving a COVID-19 test. At the beginning of the study period, documentation in the EHR for a COVID-19 admission was not fully standardized, so this allowed for inclusion of all individuals with suspected COVID-19. Definitions and documentation within the EHR became more consistent as the study period progressed. As the burden of COVID-19 increased in NYC over the study period, most admissions were in fact for COVID-19.

Conclusions

In this case series of patients tested for and hospitalized for COVID-19 at NYC's public hospital system, male sex, older age, and certain chronic diseases were significantly associated with testing positive, hospitalization, and death from COVID-19, and racial/ethnic disparities were observed across all outcomes. These findings can help inform testing and mitigation strategies in other urban areas with similarly diverse populations.

Conflict of Interest Disclosures: None reported.

Funding/Support: This study was funded in part by the Clinical & Translational Science Award grant #UL1TR001445 from the National Institutes of Health.

Role of the Funder/Sponsor: The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Group Information: The New York City Health + Hospitals COVID-19 Population Health Data Team members include Spriha Gogia, PhD, MPH; Jonie Gordon; Richa Gupta, MPH; Nicole Hosseinipour, MPH; Laura Jacobson, MSPH; Remle Newton-Dame, MPH; Lauren Schreibstein, MA; Jesse Singer, DO; Jenny Smolen, MPH; Areeba Tariq, MS; Suharika Thotakura, MS; and Christine Zhang, MPA. Acknowledgments: We would like to acknowledge all of the patients and families in New York City who have been profoundly impacted by COVID-19 and the frontline clinical teams across New York City Health + Hospitals who have worked tirelessly in their care. We are particularly grateful to Dr. Mitch Katz and Dr. Machelle Allen for their clinical leadership during this extraordinarily challenging time. We also would like to thank Sharanjit Kaur for her assistance in manuscript preparation.

References

1 New York City Department of Health and Mental Hygiene. COVID-19: Data.

https://www1.nyc.gov/site/doh/COVID/COVID-19-data.page. Accessed April 29, 2020.

² Goyal P, Choi JJ, Pinheiro LC, et al. Clinical Characteristics of COVID-19 in New York City [published online April 17, 2020]. *N Engl J Med.* doi:10.1056/NEJMc2010419

³ Petrilli CM, Jones SA, Yang J, et al. Factors associated with hospitalization and critical illness among 4,103 patients with COVID-19 disease in New York City. *MedRxiv*. 2020. doi: https://doi.org/10.1101/2020.04.08.20057794

⁴ Cumming MJ, Baldwin MR, Abrams D, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. *MedRxiv*.
2020. doi: https://doi.org/10.1101/2020.04.15.20067157

⁵ Paranjpe I, Russak A, De Freitas JK, et al. Clinical Characteristics of Hospitalized COVID-19 Patients in New York City. *MedRxiv*. 2020. doi: https://doi.org/10.1101/2020.04.19.20062117 ⁶ Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area [published online April 22, 2020]. *JAMA*. doi:10.1001/jama.2020.6775

7 Wang Z, Zheutlin AB, Kao Y, et al. Analysis of hospitalized COVID-19 patients in the Mount Sinai Health System using electronic medical records (EMR) reveals important prognostic factors for improved clinical outcomes. *MedRxiv*. 2020. doi:

https://doi.org/10.1101/2020.04.28.20075788

⁸ Wu C, Chen X, Cai Y, et al. Risk Factors Associated With Acute Respiratory Distress
Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China.
[published online March 13, 2020]. *JAMA Intern Med.* doi:10.1001/jamainternmed.2020.0994

9 Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. *JAMA*. 2020;323(11):1061–1069. doi:10.1001/jama.2020.1585

¹⁰ Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. *N Engl J Med* 2020; 382:1708-1720. doi: 10.1056/NEJMoa2002032

¹¹ Lighter J, Phillips M, Hochman S, et al. Obesity in patients younger than 60 years is a risk factor for COVID-19 hospital admission [published online April 9, 2020]. *Clin Infect Dis.* doi:10.1093/cid/ciaa415

¹² Nobel YR, Phipps M, Zucker J, et al. Gastrointestinal Symptoms and COVID-19: Case-Control Study from the United States [published online April 12, 2020]. Gastroenterology. doi:10.1053/j.gastro.2020.04.017

¹³ CDC COVID-19 Response Team. Preliminary Estimates of the Prevalence of Selected
¹³ Underlying Health Conditions Among Patients with Coronavirus Disease 2019 — United States,
February 12–March 28, 2020. *MMWR Morb Mortal Wkly Rep* 2020;69:382–386. DOI:

http://dx.doi.org/10.15585/mmwr.mm6913e2

¹⁴ Hakim D. Asthma Is Absent Among Top COVID-19 Risk Factors, Early Data Shows. *The New York Times*. April 16, 2020. https://www.nytimes.com/2020/04/16/health/coronavirusasthma-risk.html. Accessed April 20, 2020.

¹⁵ Halpin DMG, Faner R, Sibila O, Badia JR, Agusti A. Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection? [published online April 3, 2020]. *Lancet Respir Med.* DOI: 10.1016/S2213-2600(20)30167-3

16 NYC DOHMH. Age-adjusted rates of lab confirmed COVID-19. 2020 April 16. https://www1.nyc.gov/assets/doh/downloads/pdf/imm/COVID-19-deaths-race-ethnicity<u>04162020-1.pdf</u>. Accessed April 20, 2020.

17 NYC DOHMH. Age-adjusted rates of lab confirmed COVID-19. May 13, 2020.

https://www1.nyc.gov/assets/doh/downloads/pdf/imm/covid-19-deaths-race-ethnicity-05142020-

1.pdf. Accessed May 15, 2020.

¹⁸ U.S. Census Bureau. Quick Facts: New York City, New York - Population Estimates, July 1,
2019. <u>https://www.census.gov/quickfacts/newyorkcitynewyork</u>. Accessed May 18, 2020.

¹⁹ NYC DOHMH. NYC Health Data: EpiQuery. Community Health Survey 2017, Disease and Conditions. <u>https://a816-</u>

health.nyc.gov/hdi/epiquery/visualizations?PageType=ts&PopulationSource=CHS&Topic=1&S ubtopic=24. Accessed April 20, 2020.

²⁰ Dorn AV, Cooney RE, Sabin ML. COVID-19 exacerbating inequalities in the US. *Lancet*.
 2020;395(10232):1243-1244. doi:10.1016/S0140-6736(20)30893-X

21 U.S. Bureau of Labor Statistics. Economic News Release: Table 1. Workers who could work at home, did work at home, and were paid for work at home, by selected characteristics, averages for the period 2017-2018. September 24, 2020. https://www.bls.gov/news.release/flex2.t01.htm. Accessed April 20, 2020.

22 U.S. Census Bureau. Quick Facts: New York City, New York - Population Estimates, July 1, 2019. https://www.census.gov/quickfacts/newyorkcitynewyork. Accessed April 20, 2020.

23 New York City Health + Hospitals (NYC H+H). Mayor De Blasio and NYC Health +

Hospitals Expand Appointment-Only COVID-19 Testing Capacity. New York City Health +

Hospitals Press Release. March 19, 2020.

https://www.nychealthandhospitals.org/pressrelease/mayor-de-blasio-and-nyc-health-hospitalsexpand-appointment-only-COVID-19-testing. Accessed April 20, 2020. ²⁴ New York City Department of Health and Mental Hygiene (NYC DOHMH). 2020 Advisory#8: COVID-19 Update for New York City. March 20, 2020.

https://www1.nyc.gov/assets/doh/downloads/pdf/han/advisory/2020/COVID-19-03202020.pdf.

Accessed April 20, 2020.

25 NYC H+H. New Coronavirus Testing Guidelines.

https://www.nychealthandhospitals.org/coronavirus-testing-guidelines/?notification. Accessed

April 20, 2020.

		Patients by Test Result (No., %)							
		All	Negative	Positive	P value _a				
	Total	22176 (100)	8734 (39)	13442 (61)					
	Female	10965 (49)	5008 (57)	5957 (44)	Reference				
Sex	Male	11207 (51)	3726 (43)	7481 (56)	< 0.001				
	Unknown/declined	4 (0)	0 (0)	4 (0)					
	Median (IQR)	50.2 (36.6, 61.9)	45.6 (33.2, 58.0)	52.7 (39.5, 64.5)					
	0-17	491 (2)	387 (4)	104 (1)	< 0.001				
	18-44	8472 (38)	3886 (44)	4586 (34)	Reference				
Age	45-64	8847 (40)	3341 (38)	5506 (41)	< 0.001				
	65-74	2441 (11)	687 (8)	1754 (13)	< 0.001				
	75+	1925 (9)	433 (5)	1492 (11)	< 0.001				
	Black	5790 (26)	2272 (26)	3518 (26)	< 0.001				
	Hispanic	6249 (28)	1656 (19)	4593 (34)	< 0.001				
Race/ Ethnicity _b	White	2316 (10)	1151 (13)	1165 (9)	Reference				
	Asian or Pacific Islander	1739 (8)	876 (10)	863 (6)	0.400				
	Other	6013 (27)	2737 (31)	3276 (24)	0.002				
	BMI <25	6338 (40)	1652 (26)	2196 (35)	Reference				
	BMI 25 to <30	4613 (29)	1473 (32)	3127 (68)	0.004				
BMIc	BMI 30 to < 40	3973 (25)	1182 (30)	2784 (70)	< 0.001				
	BMI ≥40	904 (6)	250 (28)	652 (72)	0.002				
	Diabetes	3752 (23)	1042 (17)	2710 (27)	< 0.001				
	Hypertension	4424 (27)	1381 (22)	3043 (30)	< 0.001				
	Arrhythmia	998 (6)	364 (6)	634 (6)	0.299				
	CVD	3291 (20)	1205 (19)	2086 (21)	0.057				
	CHF	840 (5)	319 (5)	521 (5)	0.984				
	Asthma	1421 (9)	711 (11)	710 (7)	< 0.001				
Comorbiditiesd	COPD	583 (4)	299 (5)	284 (3)	< 0.001				
	Liver disease	461 (3)	188 (3)	273 (3)	0.243				
	Chronic kidney disease	1129 (7)	320 (5)	809 (8)	< 0.001				
	Cancer	1554 (9)	557 (9)	997 (10)	0.061				
	HIV	277 (2)	118 (2)	159 (2)	0.132				
	≥1 chronic disease	7072 (43)	2403 (38)	4669 (46)	< 0.001				

Table 1: Characteristics and Outcomes of Tested Patients

a P values for sex, age, race/ethnicity, and BMI are from pairwise χ_2 tests with female sex, ages 18-44, White, and BMI <25 as reference categories, respectively. P values for comorbidities are from pairwise χ_2 tests with the group without the comorbidity (not presented in the table) as the reference category.

b Race/ethnicity was available for 22107 (99.7%) patients.

c BMI was available for 15828 (71%) patients.

d Comorbidities were available for 16420 (74%) patients.

 $_{e}$ Flag for ≥ 1 chronic disease includes diabetes, hypertension, cardiovascular disease, asthma, chronic obstructive pulmonary disorder, and chronic kidney disease.

		Patients who Tested Positive by Outcome (No., %)								
		Total	Not Hospitalized	Hospitalized	P value _a					
	Total	13442 (100)	7194 (54)	6248 (46)						
	Female	5957 (44)	3561 (49)	2396 (38)	Reference					
Sex	Male	7481 (56)	3630 (50)	3851 (62)	< 0.001					
	Unknown / declined	4 (0)	3 (0)	1 (0)						
	Median (IQR)	52.7 (39.5, 64.5)	45.2 (34.5, 56.1)	61.6 (49.7, 72.9)						
	0-17	104 (1)	72 (1)	32 (1)	0.138					
Age	18-44	4586 (34)	3486 (48)	1100 (18)	Reference					
Age	45-64	5506 (41)	3015 (42)	2491 (40)	< 0.001					
	65-74	1754 (13)	451 (6)	1303 (21)	< 0.001					
	75+	1492 (11)	170 (2)	1322 (21)	< 0.001					
	Black	3518 (26)	1568 (22)	1950 (31)	< 0.001					
	Hispanic	4593 (34)	2491 (35)	2102 (34)	0.99					
Race/ Ethnicity _b	White	1165 (9)	631 (9)	534 (9)	Reference					
	Asian or Pacific Islander	863 (6)	489 (7)	374 (6)	0.28					
	Other	3276 (24)	1988 (28)	1288 (21)	< 0.001					
	BMI <25	2196 (25)	769 (25)	1427 (25)	Reference					
BMIc	BMI 25 to <30	3127 (36)	1173 (38)	1954 (35)	0.069					
	BMI 30 to < 40	2784 (32)	1009 (33)	1775 (31)	0.386					
	BMI >40	652 (7)	149 (5)	503 (9)	<.001					
	Diabetes	2710 (27)	665 (17)	2045 (33)	< 0.001					
	Hypertension	3043 (30)	756 (19)	2287 (37)	< 0.001					
	Arrhvthmia	634 (6)	115 (3)	519 (8)	< 0.001					
	CVD	2086 (21)	591 (15)	1495 (24)	< 0.001					
	CHF	521 (5)	58 (1)	463 (7)	< 0.001					
Comorbiditiesa	Asthma	710 (7)	283 (7)	427 (7)	0.668					
Comorbiantesa	COPD	284 (3)	51 (1)	233 (4)	<0.001					
	Liver disease	273 (3)	83 (2)	190 (3)	0.004					
	Chronic kidnev disease	809 (8)	103 (3)	706 (11)	< 0.001					
	Cancer	997 (10)	396 (10)	601 (10)	0.663					
	HIV	159 (2)	65 (2)	94 (2)	0.689					
	>1 chronic disease	4669 (46)	1400 (35)	3269 (53)	< 0.001					

 Table 2: Characteristics and Outcomes of Patients Testing Positive

a P values for sex, age, race/ethnicity, and BMI are from pairwise χ_2 tests with female sex, ages 18-44, White, and BMI <25 as reference categories, respectively. P values for comorbidities are from pairwise χ_2 tests with the group without the comorbidity (not presented in the table) as the reference category.

b Race/ethnicity was available for 13415 (99.8%) patients.

c BMI was available for 8759 (65%) patients.

d Comorbidities were available for 10169 (76%) patients.

 $_{e}$ Flag for ≥ 1 chronic disease includes diabetes, hypertension, cardiovascular disease, asthma, chronic obstructive pulmonary disorder, and chronic kidney disease.

		Hospitalized Patients (No., %)								
		All	Still Admitted	Discharged	Died	P value _a				
	Total	6248 (100)	1238 (20)	3286 (53)	1724 (28)					
	Female	2396 (38)	441 (36)	1318 (40)	637 (37)	Reference				
Sex	Male	3851 (62)	796 (64)	1968 (60)	1087 (63)	0.032				
	Unknown/ declined	1 (0)	1 (0)	0 (0)	0 (0)					
	Median (IQR)	61 [49.7, 72.9]	62.5 [53.6, 71.9]	56.3 [44.2, 67.7]	71 [60.0,80.9]					
	0-17	32 (1)	1 (0)	30 (1)	1 (0)					
A	18-44	1100 (18)	146 (12)	826 (25)	128 (7)	Reference				
Age	45-64	2491 (40)	561 (45)	1447 (44)	483 (28)	<.001				
	65-74	1302 (21)	298 (24)	572 (17)	433 (25)	<.001				
	75+	1322 (21)	232 (19)	411 (13)	679 (39)	<.001				
	Black	1950 (31)	376 (30)	1068 (33)	506 (29)	<.001				
	Hispanic	2102 (34)	414 (33)	1160 (35)	528 (31)	<.001				
Race/ Ethnicity	White	534 (9)	94 (8)	232 (7)	208 (12)	Reference				
Lumenty	Asian or Pacific Islander	374 (6)	78 (6)	186 (6)	110 (6)	0.008				
	Other	1288 (21%)	276 (22)	640 (19)	372 (22)	<.001				
	BMI <25	1427 (25)	302 (25)	731 (25)	394 (26)	Reference				
BMIb	BMI 25 to <30	1954 (35)	394 (33)	1059 (36)	501 (33)	0.125				
DIVIIb	BMI 30 to < 40	1775 (31)	388 (33)	945 (32)	442 (30)	0.104				
	BMI >40	503 (9)	106 (9)	238 (8)	159 (11)	0.084				
	Diabetes	2045 (33)	420 (34)	1028 (32)	597 (35)	0.032				
	Hypertension	2287 (37)	497 (40)	1151 (35)	639 (37)	0.241				
	Arrhvthmia	519 (8)	193 (11)	223 (7)	193 (11)	0.001				
	CVD	1495 (24)	297 (24)	722 (22)	476 (28)	0.001				
	CHF	463 (7)	105 (9)	199 (6)	159 (9)	0.001				
Comorbidities	Asthma	427 (7)	75 (6)	249 (8)	103 (6)	0.033				
c	COPD	233 (4)	43 (3)	121 (4)	69 (4)	0.671				
	Liver disease	190 (3)	44 (4)	99 (3)	47 (3)	0.592				
	Chronic kidnev disease	706 (11)	153 (12)	295 (9)	258 (15)	0.001				
	Cancer	601 (10)	116 (9)	305 (9)	180 (10)	0.243				
	HIV	94 (2)	16(1)	58 (2)	20 (1)	0.119				
	>1 chronic diseased	3269 (53)	673 (55)	1684 (52)	912 (53)	0.442				

Table 3: Characteristics and Outcomes of Hospitalized Patients

a P values for sex, age, race/ethnicity, and BMI are from pairwise χ_2 tests with female sex, ages 18-44, White, and BMI <25 as reference categories, respectively. P values for comorbidities are from pairwise χ_2 tests with the group without the comorbidity (not presented in the table) as the reference category.

b BMI was available for 5659 (91%) patients.

c Comorbidities were available for 6200 (99%) patients.

e Flag for ≥ 1 chronic disease includes diabetes, hypertension, cardiovascular disease, asthma, chronic obstructive pulmonary disorder, and chronic kidney disease.

	Total	Black	Hispanic	White	Asian / Pacific Islander	Other				
Tested Positive (No., %)										
0-17	103 (1)	18 (1)	49 (1)	5 (0)	6(1)	25 (1)				
18-44	4577 (34)	845 (24)	1732 (38)	340 (29)	291 (34)	1369 (42)				
45-64	5493 (41)	1576 (45)	1918 (42)	417 (36)	350 (41)	1232 (38)				
65-74	1752 (13)	574 (16)	489 (11)	180 (15)	139 (16)	370 (11)				
≥75	1490 (11)	505 (14)	405 (9)	223 (19)	77 (9)	280 (9)				
Total	13415	3518	4593	1165	863	3276				
			Hospitalized (No., %)						
0-17	32 (1)	4 (0)	17 (1)	1 (0)	1 (0)	9 (1)				
18-44	1100 (18)	219 (11)	514 (24)	46 (9)	55 (15)	266 (21)				
45-64	2491 (40)	814 (42)	873 (42)	148 (28)	140 (37)	516 (40)				
65-74	1303 (21)	462 (24)	347 (17)	126 (24)	107 (29)	261 (20)				
≥75	1322 (21)	451 (23)	351 (17)	213 (40)	71 (19)	236 (18)				
Total	6248	1950	2102	534	374	1288				
			Died (No.,	%)						
0-17	1 (0)	0 (0)	1 (0)	0 (0)	0 (0)	0 (0)				
18-44	128 (7)	25 (5)	59 (11)	5 (2)	4 (4)	34 (9)				
45-64	483 (28)	138 (27)	168 (32)	35 (17)	27 (25)	115 (31)				
65-74	433 (25)	13 (26)	115 (22)	42 (20)	37 (34)	106 (28)				
≥75	679 (39)	209 (41)	185 (35)	126 (61)	42 (38)	117 (31)				
Total	1724	506	528	208	110	372				

 Table 4: Age Distribution of Patients by Race/Ethnicity


		Hospitalized (No., %)						Died (No., %)					
		Total	Hispanic	Black	White	Asian/ Pacific Islander	Other	Total	Hispanic	Black	White	Asian/ Pacific Islander	Other
	Total	6248	2102	1950	534	374	1288	1719	527	504	207	109	372
	BMI <25	460 (25)	121 (21)	152 (24)	47 (30)	41 (40)	99 (26)	394 (26)	89 (19)	121 (28)	72 (38)	39 (39)	73 (24)
BMIa	BMI 25 to <30	658 (35)	224 (38)	191 (30)	53 (34)	42 (41)	148 (38)	501 (33)	181 (39)	129 (29)	53 (28)	38 (38)	100 (34)
DIVIIa	BMI 30 to <40	571 (34)	203 (37)	201 (37)	46 (32)	17 (17)	104 (30)	442 (30)	164 (35)	124 (28)	49 (26)	19 (19)	86 (29)
	BMI >40	168 (9)	37 (6)	83 (13)	10 (6)	2 (2)	36 (9)	159 (11)	35 (7)	65 (15)	16 (8)	4 (4)	39 (13)
	Diabetes	2045 (33)	727 (35)	757 (39)	142 (27)	110 (30)	309 (24)	597 (35)	199 (38)	217 (43)	56 (27)	35 (32)	90 (24)
	Hypertension	2287 (37)	698 (33)	949 (49)	190 (27)	126 (34)	324 (25)	639 (37)	209 (40)	228 (45)	73 (35)	37 (34)	92 (25)
	Arrhvthmia	519 (8)	140 (7)	199 (10)	78 (15)	32 (9)	70 (5)	193 (11)	58 (11)	67 (13)	36 (17)	12 (11)	20 (5)
	CVD	1495 (24)	469 (22)	553 (29)	173 (33)	89 (24)	211 (17)	476 (28)	148 (28)	149 (30)	75 (36)	35 (32)	69 (19)
	CHF	463 (7)	116 (6)	201 (10)	61 (11)	24 (7)	61 (5)	159 (9)	41 (8)	53 (11)	31 (15)	12 (11)	22 (6)
C LUIN	Asthma	427 (7)	140 (7)	163 (8)	29 (5)	12 (3)	83 (6)	103 (6)	46 (9)	27 (5)	12 (6)	3 (3)	15 (4)
Comorbidities ^b	COPD	233 (4)	52 (2)	99 (5)	31 (6)	10 (3)	41 (3)	69 (4)	21 (4)	20 (4)	14 (7)	7 (6)	7 (2)
	Liver disease	190 (3)	84 (4)	56 (3)	17 (3)	9 (2)	24 (2)	47 (3)	19 (4)	11 (2)	5 (2)	3 (3)	9 (2)
	Chronic kidnev	706 (11)	186 (9)	326 (17)	57 (11)	41 (11)	96 (8)	258 (15)	64 (12)	106 (21)	32 (15)	21 (19)	35 (9)
	Cancer	601 (10)	218 (10)	235 (12)	47 (9)	37 (10)	64 (5)	180 (10)	71 (13)	59 (12)	14 (7)	14 (13)	22 (6)
	HIV	94 (2)	27 (1)	45 (2)	6 (1)	2 (1)	14 (50)	20(1)	9 (2)	8 (2)	1 (0)	0 (0)	2 (1)
	≥1 chronic diseasec	3269 (53)	1048 (50)	1236 (64)	278 (52)	180 (49)	527 (41)	912 (53)	286 (54)	310 (62)	111 (54)	56 (51)	149 (40)


Table 5: Comorbidities of Patients by Race/Ethnicity

^a BMI was available for 5659 (91%) hospitalized patients and 1496 (87%) patients who died.
^b Comorbidities were available for 6200 (99%) hospitalized patients and 1719 (99.7%) patients who died.

 \circ Flag for ≥ 1 chronic disease includes diabetes, hypertension, cardiovascular disease, asthma, chronic obstructive pulmonary disorder, and chronic kidney disease.


Figure 1: Flow Diagram of Included Patients















Test result by age




Test result by race/ethnicity







Hospitalization by age



Hospitalization by race/ethnicity






Figure 4: Death by Demographic Factors



Death by age



Death by race/ethnicity